Hypertensive disease
|
0.570 |
Biomarker
|
group |
BEFREE |
Drugs targeting CB1R, CB2R, TRPV1 and PPARs are proven effective in animal models mimicking cardiovascular disorders such as hypertension, atherosclerosis and myocardial infarction.
|
29222605 |
2018 |
Hypertensive disease
|
0.570 |
GeneticVariation
|
group |
BEFREE |
The results obtained in the codominant and overdominant models for the <i>PPAR-y</i> polymorphism showed a tendency to statistical significance (the C/G genotype inclined to hypertriglyceridemia), and were statistically significant in the codominant, dominant, and recessive models (the C/C genotype predisposed to increased blood pressure).
|
29315078 |
2018 |
Hypertensive disease
|
0.570 |
Biomarker
|
group |
BEFREE |
The biological actions of PPARα and PPARγ and their potential as a cardiovascular therapeutic target have been extensively reviewed, whereas the biological actions of PPARβ/δ and its effectiveness as a therapeutic target in the treatment of hypertension remain less investigated.
|
27881385 |
2017 |
Hypertensive disease
|
0.570 |
Biomarker
|
group |
BEFREE |
Importantly, TAFIa inhibitor and peroxisome proliferator-activated receptor-α agonists significantly reduced TAFIa and ameliorated animal models of pulmonary hypertension in mice and rats.
|
28289017 |
2017 |
Hypertensive disease
|
0.570 |
Biomarker
|
group |
CTD_human |
These data suggest that increased PPARalpha expression is a protective mechanism in hypertensive renal injury induced by nitric oxide withdrawal/high salt diet and that siRNAs targeting the DNA-binding domain of PPARalpha gene elicited differential effects on hypertension and kidney injury.
|
19834340 |
2009 |
Hypertensive disease
|
0.570 |
Therapeutic
|
group |
CTD_human |
These data suggest that increased PPARalpha expression is a protective mechanism in hypertensive renal injury induced by nitric oxide withdrawal/high salt diet and that siRNAs targeting the DNA-binding domain of PPARalpha gene elicited differential effects on hypertension and kidney injury.
|
19834340 |
2009 |
Hypertensive disease
|
0.570 |
Biomarker
|
group |
RGD |
Skeletal muscle characteristics of rats with obesity, diabetes, hypertension, and hyperlipidemia.
|
19763017 |
2009 |
Hypertensive disease
|
0.570 |
GeneticVariation
|
group |
BEFREE |
Making the THM animals deficient in Peroxisome proliferator-activated receptor-alpha (THM/PPARKO) totally abolished hypertension and myocardial hypertrophy.
|
17909121 |
2007 |
Hypertensive disease
|
0.570 |
Therapeutic
|
group |
CTD_human |
Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.
|
16054168 |
2005 |
Hypertensive disease
|
0.570 |
Therapeutic
|
group |
RGD |
Therefore, chronic PPAR-alpha agonist treatment reduces salt-dependent hypertension produced by ETB receptor blockade in male and female Sprague-Dawley rats.
|
15967866 |
2005 |
Hypertensive disease
|
0.570 |
Biomarker
|
group |
CTD_human |
Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity.
|
16054168 |
2005 |
Hypertensive disease
|
0.570 |
GeneticVariation
|
group |
BEFREE |
Hypertension linked to the PPAR-gamma2 Pro allele carriers was characterized by high leptin output during OLTT.
|
15202783 |
2004 |
Hypertensive disease
|
0.570 |
GeneticVariation
|
group |
BEFREE |
We demonstrate that variation in the PPARalpha gene influences human left ventricular growth in response to exercise and hypertension, indicating that maladaptive cardiac substrate utilization can play a causative role in the pathogenesis of LVH.
|
11864924 |
2002 |
Hypertensive disease
|
0.570 |
GeneticVariation
|
group |
LHGDN |
We demonstrate that variation in the PPARalpha gene influences human left ventricular growth in response to exercise and hypertension, indicating that maladaptive cardiac substrate utilization can play a causative role in the pathogenesis of LVH.
|
11864924 |
2002 |